Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for STELARA® ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Johnson & Johnson (JNJ) PT Raised to $142 at Stifel on 3Q Earnings Report; 'Pharma Carries the Day, Hurricane Headwinds Encouragingly ModestOctober 17, 2017 5:16 PM Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque PsoriasisOctober 13, 2017 4:20 PM